ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >protein tyrosine kinase >AZD-9291

AZD-9291

AZD-9291 Suppliers list
Company Name: Hebei Mojin Biotechnology Co., Ltd
Tel: +8613288715578
Email: sales@hbmojin.com
Products Intro: Product Name:AZD-9291
CAS:1421373-65-0
Purity:99% Package:25KG
Company Name: shandong perfect biotechnology co.ltd
Tel: +86-53169958659; +8618596095638
Email: sales@sdperfect.com
Products Intro: Product Name:Osimertinib (AZD9291)
CAS:1421373-65-0
Purity:98% HPLC Package:1g
Company Name: Henan Bao Enluo International TradeCo.,LTD
Tel: +86-17331933971 +86-17331933971
Email: deasea125996@gmail.com
Products Intro: Product Name:AZD-9291
CAS:1421373-65-0
Purity:99.9% Package:1kg;50USD
Company Name: SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.
Tel: +86-0531-69954981 +8615666777973
Email: dwyane.wang@boyuanpharm.com
Products Intro: Product Name:Osimertinib
CAS:1421373-65-0
Purity:99.9% HPLC Package:1kg;|5kg;|10kg
Company Name: Capot Chemical Co.,Ltd.
Tel: 571-85586718 +8613336195806
Email: sales@capotchem.com
Products Intro: Product Name:Osimertinib
CAS:1421373-65-0
Purity:NLT 98% Package:1G;1KG;100KG

AZD-9291 manufacturers

  • Osimertinib (AZD9291)
  • Osimertinib (AZD9291) pictures
  • $0.00 / 1g
  • 2024-03-12
  • CAS:1421373-65-0
  • Min. Order: 1g
  • Purity: 98% HPLC
  • Supply Ability: 1KG
  • AZD-9291
  • AZD-9291 pictures
  • $0.00 / 10g
  • 2023-11-27
  • CAS:1421373-65-0
  • Min. Order: 10g
  • Purity: 99%
  • Supply Ability: 50kg
  • Osimertinib
  • Osimertinib  pictures
  • $0.00 / 1kg
  • 2023-09-07
  • CAS:1421373-65-0
  • Min. Order: 1kg
  • Purity: 99.9% HPLC
  • Supply Ability: 1000
AZD-9291 Basic information
Uses
Product Name:AZD-9291
Synonyms:N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide;Mereletinib mesylate(AZD9291);AZD9291 (free base);Osimertinib (AZD-9291);AZD9291, Osimertinib;AZD9291 Base;Osimertinib Base;AZD9291 10G
CAS:1421373-65-0
MF:C28H33N7O2
MW:499.61
EINECS:629-848-5
Product Categories:Inhibitors;API;Anticancer;AZD9291;1421373-65-0
Mol File:1421373-65-0.mol
AZD-9291 Structure
AZD-9291 Chemical Properties
Melting point >188oC (dec.)
density 1.19±0.1 g/cm3(Predicted)
storage temp. Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility DMSO (Slightly, Heated), Methanol (Slightly, Heated)
pka12.68±0.70(Predicted)
form Solid
color Pale Yellow to Beige
CAS DataBase Reference1421373-65-0
Safety Information
HS Code 29339900
MSDS Information
AZD-9291 Usage And Synthesis
UsesAZD-9291 (Osimertinib) is a oral, third generation, small-molecule epidermal growth factor receptor (EGFR) inhibitor and antineoplastic agent. In addition, it is a Cytochrome P450 3A inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 1A2 Inducer, and Breast Cancer Resistance Protein Inhibitor. It is used for the treatment of advanced non-small cell lung cancer (NSCLC) where mutant EGFR form (such as T790M) is often presented. Through suppressing the EGFR-mediated signalling, it cause cell death and inhibit tumour growth in related cancer cells. 
DescriptionAZD-9291 (Mesylate), also known as Osimertinib, belongs to a third-generation EGFR (epidermal growth factor receptor) inhibitor. It can be used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in case when the cancer cells carry specific mutations (such as T790M) in the epidermal growth factor receptor. It takes effect through directly binding to the certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) that are frequently found in NSCLC, further causing poor prognosis for late-stage disease. Since it spares wild type EGFR during therapy, it has only limited toxicity.
UsesAZD 9291 is an irreversible inhibitor of epidermal growth factor receptor (EGFR) sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type form of the receptor (IC50 = 480 nM). It binds the related IGF1R and hERG receptors with significantly reduced potency (IC50s = 2.9 and 16.2 μM, respectively). AZD 9291 has been shown to inhibit tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg and has been tested clinically in patients with advanced EGFR mutant non-small-cell lung cancer.[Cayman Chemical]
IndicationsThe collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee.
DefinitionChEBI: A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treat ent of EGFR T790M mutation positive non-small cell lung cancer.
targetExon 19 deletion EGFR
Referenceshttp://www.medkoo.com/products/6711
https://en.wikipedia.org/wiki/Osimertinib
https://www.drugbank.ca/drugs/DB09330
Tag:AZD-9291(1421373-65-0) Related Product Information
3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide Osimertinib dimesylate Osimertinib mesylate 3,5-Dimethyl-4-methoxy-2-pyridinemethanol N-(2-(dimethylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide Olmutinib XL-647 Genistein AZD 3759 AG 1478 HYDROCHLORIDE OSI-420 Anlotinib EGF816 Tucatinib Neratinib Poziotinib (HM781-36B) Dacomitinib (PF299804) Bortezomib